MolPharm Over 1500 Individual Drug Articles!

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on July 5, 2005; DOI: 10.1124/mol.105.013516


0026-895X/05/6804-1074-1078$20.00
Mol Pharmacol 68:1074-1078, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.013516v1
68/4/1074    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hwang, G.-W.
Right arrow Articles by Naganuma, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hwang, G.-W.
Right arrow Articles by Naganuma, A.

Overexpression of Rad23 Confers Resistance to Methylmercury in Saccharomyces cerevisiae via Inhibition of the Degradation of Ubiquitinated Proteins

Gi-Wook Hwang, Daisuke Sasaki, and Akira Naganuma

Laboratory of Molecular and Biochemical Toxicology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (G.-W.H., D.S., A.N.); and Tohoku University 21st Century COE Program "Comprehensive Research and Education Center for Planning of Drug Development and Clinical Evaluation", Sendai, Japan (G.-W.H., A.N.)

We report here that overexpression of Rad23, a protein related to the ubiquitin-proteasome system, renders yeast cells resistant to methylmercury. Rad23 has three domains: two ubiquitin-associated (UBA) domains that bind to the multiubiquitin chain of ubiquitinated proteins and a single ubiquitin-like (UbL) domain that binds to proteasomes. To examine the mechanism of acquisition of methylmercury resistance that is induced by overexpression of Rad23, we expressed variants of Rad23 in which one or the other of the two types of domain was defective in yeast cells. In cells that overexpressed full-length intact Rad23, we detected elevated levels of intracellular ubiquitinated proteins, and the cells were resistant to methylmercury. In contrast, cells that overexpressed Rad23 with a defective UBA domain were not resistant to methylmercury and contained control levels of ubiquitinated proteins. Yeast cells that overexpressed Rad23 with a defective UbL domain exhibited enhanced resistance to methylmercury and contained even higher levels of ubiquitinated proteins than cells that overexpressed intact full-length Rad23. Rad23 is known to have two mutually contradictory functions. It suppresses the degradation of ubiquitinated proteins by proteasomes via a mechanism mediated by the UBA domains, and it enhances the degradation of ubiquitinated proteins via a mechanism that is mediated by the UbL domain. Therefore, our findings suggest that Rad23 might induce resistance to methylmercury in yeast cells by suppressing the degradation of proteins that reduce the toxicity of methylmercury via a UBA domain-mediated mechanism.


Received April 6, 2005; accepted July 5, 2005

Address correspondence to: Dr. Akira Naganuma, Laboratory of Molecular and Biochemical Toxicology, Graduate School of Pharmaceutical Sciences, Tohoku University, Aoba-ku, Sendai 980-8578, Japan. E-mail: naganuma{at}mail.pharm.tohoku.ac.jp




This article has been cited by other articles:


Home page
Cancer Res.Home page
T. Takahashi, T. Furuchi, and A. Naganuma
Endocytic Ark/Prk Kinases Play a Critical Role in Adriamycin Resistance in Both Yeast and Mammalian Cells
Cancer Res., December 15, 2006; 66(24): 11932 - 11937.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics